Claims
- 1. A method for antagonizing downregulation of the expression of MHC Class II molecules by dendritic cells comprising contacting the dendritic cells with an effective amount of a soluble VESPR protein comprising a VESPR polypeptide consisting of an amino acid sequence at least 90% identical to SEQ ID NO:2, wherein the VESPR polypeptide can bind to a semaphorin selected from the group consisting of A39R semaphorin and AHV semaphorin.
- 2. The method of claim 1, wherein the soluble VESPR protein is a VESPR polypeptide fusion comprising a second polypeptide.
- 3. The method of claim 2, wherein the second polypeptide comprises an Fc region of an antibody.
- 4. The method of claim 1, wherein the VESPR polypeptide comprises an amino acid sequence at least 90% identical to amino acids 35-944 of SEQ ID NO:2.
- 5. The method of claim 4, wherein the VESPR polypeptide comprises amino acids 35-944 of SEQ ID NO:2.
- 6. The method of claim 1, wherein the dendritic cells are contacted with the soluble VESPR protein in vivo.
- 7. The method of claim 1, whereby downregulation of the expression of CD86 by the dendritic cells is antagonized.
- 8. The method of claim 1, whereby upregulation of the expression of CD69 by the dendritic cells is antagonized.
- 9. The method of claim 1, whereby upregulation of the expression of IL-12 by the dendritic cells is antagonized.
- 10. A method for antagonizing upregulation of the expression of CD54 by monocytes comprising contacting the monocytes with an effective amount of a soluble VESPR protein comprising a VESPR polypeptide consisting of an amino acid sequence at least 90% identical to SEQ ID NO:2, wherein the VESPR polypeptide can bind to a semaphorin selected from the group consisting of A39R semaphorin and AHV semaphorin.
- 11. The method of claim 10, wherein the soluble VESPR protein is a VESPR polypeptide fusion comprising a second polypeptide.
- 12. The method of claim 11, wherein the second polypeptide comprises an Fc region of an antibody.
- 13. The method of claim 10, wherein the VESPR polypeptide comprises an amino acid sequence at least 90% identical to amino acids 35-944 of SEQ ID NO:2.
- 14. The method of claim 13, wherein the VESPR polypeptide comprises amino acids 35-944 of SEQ ID NO:2.
- 15. The method of claim 10, wherein the monocytes are contacted with the soluble VESPR protein in vivo.
- 16. A method for antagonizing upregulation of the expression of IL-12 by dendritic cells comprising contacting the dendritic cells with an effective amount of a soluble VESPR protein comprising a VESPR polypeptide consisting of an amino acid sequence at least 90% identical to SEQ ID NO:2, wherein the VESPR polypeptide can bind to a semaphorin selected from the group consisting of A39R semaphorin and AHV semaphorin.
- 17. The method of claim 16, wherein the soluble VESPR protein is a VESPR polypeptide fusion comprising a second polypeptide.
- 18. The method of claim 17, wherein the second polypeptide comprises an Fc region of an antibody.
- 19. The method of claim 16, wherein the VESPR polypeptide comprises an amino acid sequence at least 90% identical to amino acids 35-944 of SEQ ID NO:2.
- 20. The method of claim 19, wherein the VESPR polypeptide comprises amino acids 35-944 of SEQ ID NO:2.
- 21. The method of claim 16, wherein the dendritic cells are contacted with the soluble VESPR protein in vivo.
- 22. The method of claim 16, whereby upregulation of the expression of CD69 by the dendritic cells is antagonized.
- 23. The method of claim 16, whereby downregulation of the expression of MHC Class II molecules and CD86 by the dendritic cells is antagonized.
CROSS REFERENCE
[0001] This application is a continuation of U.S. patent application Ser. No. 09/459,061, filed Dec. 10, 1999, currently pending, which is a divisional of U.S. patent application Ser. No. 09/181,706, filed Oct. 28, 1998, now issued as U.S. Pat. No. 6,130,068, which is a continuation of U.S. patent application Ser. No. 08/958,598, filed Oct. 28, 1997, converted to a provisional application, U.S. Patent Application No. 60/112,009, on Oct. 26, 1998, now abandoned, the disclosures of which are incorporated by reference herein.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60112009 |
Oct 1997 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09181706 |
Oct 1998 |
US |
Child |
09459061 |
Dec 1999 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09459061 |
Dec 1999 |
US |
Child |
10294055 |
Nov 2002 |
US |
Parent |
08958598 |
Oct 1997 |
US |
Child |
09181706 |
Oct 1998 |
US |